Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of vilobelimab alone or vilobelimab + pembrolizumab in PD-1/PD-L1-resistant cutaneous squamous cell carcinoma
2020-000864-42Phase 2Completed
- Sponsor
- InflaRx
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of vilobelimab in cutaneous squamous cell carcinoma (cSCC) and squamous cell carcinoma (SCC) (2 arms), sponsored by InflaRx. Started Oct 2020; status: completed.
02
Drugs
vilobelimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on 2020-000864-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000864-42.